Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of heart failure pharmacotherapy in responders to cardiac resynchronization therapy
2021-001327-41Phase 4Active
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Jun 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of furosemide, bisoprolol, eplerenone and valsartan in heart failure (HF) and Cardiomyopathies (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoints: Relapse of cardiomyopathy after medication withdrawal, Change in left ventricular ejection fraction and 2 more. Started Jun 2021; status: active.
02
Drugs
furosemidebisoprololeplerenonevalsartan
03
Conditions
heart failure (HF)Cardiomyopathies
Beyond the preview
Go deeper on 2021-001327-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001327-41.